VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Nov. 1, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that dosing has been completed in a Phase Ib human clinical trial evaluating the Company’s product AL-108 as a treatment for Alzheimer’s disease.
